S
Stefan Gross
Researcher at Agios Pharmaceuticals
Publications - 81
Citations - 9306
Stefan Gross is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 30, co-authored 63 publications receiving 8086 citations. Previous affiliations of Stefan Gross include University of Pennsylvania & Tufts University.
Papers
More filters
Journal ArticleDOI
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang,David W. White,Stefan Gross,Bryson D. Bennett,Mark A. Bittinger,Edward M. Driggers,Valeria Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin Marks,Robert M. Prins,Patrick S. Ward,Katharine E. Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Matthew G. Vander Heiden,Shinsan M. Su +20 more
TL;DR: It is shown that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG), and that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross,Rob A. Cairns,Mark D. Minden,Edward M. Driggers,Mark A. Bittinger,Hyun Gyung Jang,Masato Sasaki,Shengfang Jin,David P. Schenkein,Shinsan M. Su,Lenny Dang,Valeria Fantin,Tak Mak +12 more
TL;DR: IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML, providing an explanation for the heterozygous acquisition of these mutations during tumorigenesis.
Journal ArticleDOI
Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation
Peppi Koivunen,Sungwoo Lee,Christopher G. Duncan,Giselle Y. Lopez,Gang Lu,Shakti Ramkissoon,Julie-Aurore Losman,Päivi Joensuu,Ulrich Bergmann,Stefan Gross,Jeremy Travins,Samuel Weiss,Ryan E. Looper,Keith L. Ligon,Roel G.W. Verhaak,Hai Yan,William G. Kaelin,William G. Kaelin +17 more
TL;DR: Findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Journal ArticleDOI
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Tammie C. Yeh,Vivienne Marsh,Bryan Bernat,Josh Ballard,Heidi Colwell,Ronald Evans,Janet Parry,Darin Smith,Barbara J. Brandhuber,Stefan Gross,Allison L. Marlow,Hurley Brian T,Lyssikatos Joseph P,Patrice Lee,James D. Winkler,Kevin Koch,Eli M. Wallace +16 more
TL;DR: ARRY-142886 is a potent and selective MEK1/2 inhibitor that is highly active in both in vitro and in vivo tumor models.